WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> Posts navigation Older postsNewer posts